Fig. 2From: TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinomaProgression-free survival time in the three groupsmPFS: Control group,9.3 months (95% CI 8.4–10.2 months); Entecavir group,15.5 months (95% CI 14.3–16.6 months); Tenofovir group,16.6 months (95% CI 15.1–18.2 months)Back to article page